Please use this identifier to cite or link to this item:
Title: Study of Aptamer for Cancer Therapeutics
Authors: TAN LIHAN
Keywords: aptamer, mucin 1 protein, gold nanoparticle-based affinity assay, targeted cancer drug delivery, doxorubicin, macrophage evasion
Issue Date: 5-Jul-2012
Source: TAN LIHAN (2012-07-05). Study of Aptamer for Cancer Therapeutics. ScholarBank@NUS Repository.
Abstract: In this thesis, the use of aptamers in cancer therapy was investigated in four subprojects. Firstly, a sensitive and facile gold nanoparticle based assay [with a detection limit of 8 nM mucin 1 (MUC1) peptide] was developed for peptide-aptamer affinity analysis. Secondly, MUC1 targeting aptamer was modified with polyethylene glycol to avoid macrophage uptake. Thirdly, MUC1 targeting aptamer was modified to form tridentate aptamer to increase specificity toward MUC1 overexpressing breast cancer cells as compared to macrophages. Doxorubicin (DOX) was then intercalated within the modified aptamers, and the drug-aptamer complexes used for targeted drug delivery to breast cancer cells. Through these modifications, around 6-fold increase in macrophage viability (as compared to when free DOX was used) was achieved. Finally, various newly reported affinity ligands were assessed for their potential uses in bladder cancer drug delivery.
Appears in Collections:Ph.D Theses (Open)

Show full item record
Files in This Item:
File Description SizeFormatAccess SettingsVersion 
TanLH.pdf3.61 MBAdobe PDF



Page view(s)

checked on Dec 18, 2017


checked on Dec 18, 2017

Google ScholarTM


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.